MODERN APPROACH TO DRUG THERAPY FOR BENIGN PROSTATIC HYPERPLASIA

Abstract

Benign prostatic hyperplasia (BPH) is the most common urological disease in the elderly and senile. Before the age of 40, microscopic examination reveals hyperplasia of the paraurethral glands in almost 20% of men. After 40 years, this figure reaches 40%, and by 80 years – 90% [1, 2]. The progressive development of prostatic hyperplasia underlies the occurrence of clinical symptoms of the lower urinary tract (LUTS) caused by bladder outlet obstruction, acute or chronic urinary retention, bladder stones, vesicoureteral reflux, urinary tract infection, bilateral ureterohydronephrosis and chronic renal failure. If the above manifestations are present it is necessary to resort to surgical treatment. But there is another group of men, more numerous, who have symptoms of the disease, but there are no indications for surgery. Introduced in 2001 year in Geneva in the materials of the European Urological Association, data from a survey of patients with lower urinary tract symptoms due to BPH, indicate that 58% of men deliberately reduce fluid intake in the evening; 41% avoid visiting places where there is no toilet; 31% refuse to travel long distances distances.